[EN] AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS D'AZOLOPYRIDINE ET D'AZOLOPYRIMIDINE ET MÉTHODES D'UTILISATION ASSOCIÉES
申请人:AMBIT BIOSCIENCES CORP
公开号:WO2012030924A1
公开(公告)日:2012-03-08
Provided herein are azolopyridine and azolopyrimidine compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use
申请人:Mann Grace
公开号:US20090298830A1
公开(公告)日:2009-12-03
This invention relates to certain pyrimidine derivative inhibitors of JAK-2, having Formula (I): wherein D, E, L, Z, R
1
, R
2
, R
25
, and n1 are as defined in the specification, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof.
AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF
申请人:Chao Qi
公开号:US20130303533A1
公开(公告)日:2013-11-14
Provided herein are azolopyridine and azolopyrimidine compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
[EN] 4-ARYL-2-AMINO-PYRIMIDINES OR 4-ARYL-2-AMINOALKYL-PYRIMIDINES AS JAK-2 MODULATORS AND METHODS OF USE<br/>[FR] 4-ARYL-2-AMINO-PYRIMIDINES OU 4-ARYL-2-AMINOALKYL-PYRIMIDINES UTILISÉES COMME MODULATEURS DE LA JAK-2 ET LEURS PROCÉDÉS D'UTILISATION
申请人:EXELIXIS INC
公开号:WO2007089768A2
公开(公告)日:2007-08-09
[EN] This invention relates to certain pyrimidine derivative inhibitors of JAK-2, having Formula (I): wherein D, E, L, Z, R1, R2, R25, and n1 are as defined in the specification, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof. [FR] La présente invention concerne certains inhibiteurs de la JAK-2, dérivés de la pyrimidine, de la formule (I) : D, E, L, Z, R1, R2, R25 et n1 étant tels que définis dans la description, des sels pharmaceutiquement acceptables de ceux-ci, des compositions pharmaceutiques de ceux-ci et leurs procédés d'utilisation.